Clinical Trial Access in Low- and Middle-Income Countries: A Case Study on India

Desai, Aakash; Sirohi, Bhawna; Mathew, Aju

doi:10.1080/07357907.2021.1912078

Search citation statements

Order By: Relevance

Paper Sections

Select...

Camel-sq Study1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, since the above studies were predominantly done in Asia, there is a concern about the potential lack of generalizability of the data in the population of the US and other nations. However, we hope these agents may prove to be an opportunity to improve access and affordability of immunotherapies in low-middle income countries, which has been an ongoing issue (30,31).…”

Section: Camel-sq Studymentioning

confidence: 99%

Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022

Arora

Asawa

Kataria

et al. 2022

Cancer Investigation

View full text Add to dashboard Cite

The recently concluded European Lung Cancer Congress 2022 (ELCC22) showcased some very exciting data, with more than 200 abstracts presented during the meeting. Through this review, we focus on selected clinically relevant abstracts that in our opinion represent significant updates in the current management of non-small cell lung cancer (NSCLC). Here, we summarize the updates in surgical management, adjuvant therapy and therapy for advanced stage NSCLC and put these advances in the context of the current clinical standard of care.

show abstract

Section: Camel-sq Studymentioning

confidence: 99%